drugmaker

Valeant to drop deal-making in near term to cut debt, boost stock

Valeant Pharmaceuticals International Inc (VRX.TO) is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.

Read Full Article

When companies flee U.S. tax system, investors often don't reap big returns

Establishing a tax domicile abroad to avoid U.S. taxes is a hot strategy in corporate America, but many companies that have done such "inversion" deals have failed to produce above-average returns for investors, a Reuters analysis has found.

Read Full Article

Vivus tells investors it is open to settlement

Vivus wanted to reach a settlement with the biggest investors for board control.

Read Full Article

Chilean drugmaker CFR bids for Adcock for US$1.3 billion

Adcock Ingram Holdings Ltd. received a non-binding proposal from Chilean drug manufacturer CFR Pharmaceuticals SA for US$1.3 billion.

Read Full Article

India Cipla to Take Over South Africa Cipla

Cipla Ltd offers to take over Cipla Medpro South Africa.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics